Corsair Pharma

Corsair Pharma, Inc. is a privately held clinical-stage biopharmaceutical company developing proprietary prodrugs of treprostinil for the treatment of pulmonary arterial hypertension (PAH). Its lead program, the TRX-248 transdermal system, is an investigational once-daily patch that delivers an inactive treprostinil prodrug across the skin for conversion to active drug in the liver, aiming to combine the efficacy and titration profile of parenteral prostacyclin therapy with non-invasive once-daily dosing. The company completed its preclinical program, announced positive Phase 1 results for TRX-248 in June 2026, closed a $23M Series B led by New Rhein Healthcare Investors, and has entered a strategic collaboration with United Therapeutics to advance novel treprostinil prodrugs. Corsair Pharma is a drug developer, not a software vendor: its public web presence is a five-page marketing and investor-news site with no developer program, API, SDK, or machine-readable specification of any kind.

Corsair Pharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Life Sciences, and Drug Development.

Corsair Pharma’s developer surface includes engineering blog and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub
10.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyPharmaceuticalsBiotechnologyLife SciencesDrug DevelopmentClinical TrialsPulmonary Arterial HypertensionTransdermal Delivery

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 10.8/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/corsair-pharma: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Corsair Pharma Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 3

The organization behind the API

Website
Website
 Blog
Blog
 BlogRSS
BlogRSS

Source (apis.yml)

apis.yml Raw ↑ 
aid: corsair-pharma
name: Corsair Pharma
description: 'Corsair Pharma, Inc. is a privately held clinical-stage biopharmaceutical company developing proprietary prodrugs
  of treprostinil for the treatment of pulmonary arterial hypertension (PAH). Its lead program, the TRX-248 transdermal system,
  is an investigational once-daily patch that delivers an inactive treprostinil prodrug across the skin for conversion to
  active drug in the liver, aiming to combine the efficacy and titration profile of parenteral prostacyclin therapy with non-invasive
  once-daily dosing. The company completed its preclinical program, announced positive Phase 1 results for TRX-248 in June
  2026, closed a $23M Series B led by New Rhein Healthcare Investors, and has entered a strategic collaboration with United
  Therapeutics to advance novel treprostinil prodrugs. Corsair Pharma is a drug developer, not a software vendor: its public
  web presence is a five-page marketing and investor-news site with no developer program, API, SDK, or machine-readable specification
  of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/corsair-pharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-11'
modified: '2026-08-11'
image: https://static.wixstatic.com/media/eb8f76_be22d65dbdb84f7dbd3bae3f30cf754e~mv2.png
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Drug Development
- Clinical Trials
- Pulmonary Arterial Hypertension
- Transdermal Delivery
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/corsair-pharma-domain-security.yml
- type: Website
  url: https://www.corsairpharma.com/
- type: Blog
  url: https://www.corsairpharma.com/news
- type: BlogRSS
  url: https://www.corsairpharma.com/blog-feed.xml
- type: PrivacyPolicy
  url: https://www.corsairpharma.com/privacy-policy
- type: TermsOfService
  url: https://www.corsairpharma.com/terms-of-use
x-enrichment:
  date: '2026-08-11'
  status: minimal
  pass: local-v1
  artifacts_added: 2
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Corsair Pharma is a clinical-stage drug developer whose entire web presence is a five-page Wix marketing site (home,
    news, team, privacy-policy, terms-of-use) with no developer, API, docs or partner section; the live host additionally
    answers every path with a SiteGround "Robot Challenge Screen" (HTTP 202), so the page inventory and the absence of any
    /.well-known document were confirmed from Wayback Machine captures instead.
  evidence:
  - url: https://www.corsairpharma.com/
    status: 202
  - url: https://www.corsairpharma.com/openapi.json
    status: 202
  - url: http://web.archive.org/web/2025id_/https://www.corsairpharma.com/developers
    status: 404
  - url: https://web.archive.org/web/20240405094716/https://www.corsairpharma.com/.well-known/security.txt
    status: 404
  - url: https://api.github.com/orgs/corsairpharma
    status: 404
  - url: https://pypi.org/pypi/corsair-pharma/json
    status: 404
  checked: '2026-08-11'